Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has entered into a strategic collaboration with Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") disorders. Shire will receive rights to commercialize all forms of AT-1001 outside of the United States and Japan. Alba will retain all rights to commercialize AT-1001 in the United States and Japan.

Under the terms of the collaboration, Alba will receive an initial, non- refundable licensing payment of US$ 25 million. Joint development costs toward global approval of AT-1001 will be shared 50/50 after the completion of two Phase 2 studies for Celiac disease. Alba is eligible to receive over US$ 80 million if certain clinical, regulatory and launch milestones are met for certain GI indications. Additional milestone payments totaling over US$ 40 million per indication will also be payable to Alba if the Collaboration is expanded beyond GI indications. Alba is also eligible to receive up to US$ 220 million in sales-based milestones, as well as tiered royalties. Not including royalties and cost sharing, the deal is valued at over US$ 325 million if all milestones are achieved.

Dr. Blake M. Paterson, Alba's President & CEO said:

"We are pleased to enter into this partnership with Shire, which leverages the unique experience and expertise of both companies in developing therapies for GI disorders. The combination of Alba's barrier function technology and autoimmune development capabilities with Shire's proven track record in GI drug development and commercialization will greatly enhance our efforts to bring these novel therapies to patients."

Matthew Emmens, Shire's CEO said:

"Alba's products have the potential to be an excellent addition to our current gastrointestinal business. This technology should provide significant benefit to patients w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Spartan Bioscience announced today that ... System . It detects CYP2C19 genetic mutations in less ... The Spartan RX CYP2C19 System is the first near-patient ... in Canada. Due to the system’s ease of use, ... by healthcare professionals such as doctors, nurses, pharmacists, and ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... that devastated a wide swath of Colorado last year ... and other infrastructure had been upgraded or modernized, according ... Denver. , "People need to understand the importance and ... of structural engineering at the CU Denver College of ... "There is an assumption that a bridge will stand ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... Cell Assurance, Inc. (SCLZ.PK) announced today that it has ... 10 pursuant to Section 12(g) of the Securities Exchange Act ... of December 31, 2009 and 2010 and for the years ... the Company will become an SEC reporting company and will ...
... Healthcare (NYSE: SI ) has appointed Gregory ... Healthcare in the U.S.A., effective June 1.  Sorensen succeeds ... Sorensen will also oversee the Canadian activities of Siemens ... Sorensen will be responsible for leading the marketing, ...
... Rules-Based Medicine, Inc. a leading provider of multiplexed protein ... Pasteur research project Milieu Interieur (the environment ... government.  The project will rely on RBM,s TruCulture®, an ... cellular interactions, to more accurately describe the complexities of ...
Cached Biology Technology:Gregory Sorensen to Head Siemens Healthcare U.S. and Canada Organizations 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 3Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 4
(Date:10/29/2014)... 27, 2014 — Cambridge, MA and Hebei, China — ... complete, high quality sequencing of the Jujube genome. Jujube ... family, and the Jujube genome is particularly difficult to ... complicating factors. It is the first time that a ... This study has been recently published in ...
(Date:10/29/2014)... on a large cohort of kidney cancer patients in ... disease -- and reveals an apparent link between exposure ... in Romania. , The research, by an international team ... Quebec Innovation Centre in Montreal, underscores the importance of ... compound, found in plants of the Aristolochia genus, also ...
(Date:10/28/2014)... Institute of Health (NIH) announced awards to expand ... the National Center for Advancing Translational Sciences (ORDR-NCATS) ... Through the network, physician scientists at 22 consortia ... advance clinical research and investigate new treatments for ... possible by $29 million in fiscal 2014 funding ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... is available in German . , It is ... fate of individual cells during the early development of organisms. ... of molecular biologists led by Pia Aanstad of the University ... for the interpretation of the concentration of the signaling molecule ...
... Global Crop Diversity Trust announced today numerous new grant ... seed samples maintained in 1,500 crop genebanks around the ... protect food production from the ravages of climate change. ... innovative projects, including a search in Southeast Asia and ...
... experimental vaccine applied the surface of the skin appears ... Scientists from the Research Institute at Nationwide Children,s Hospital ... 109th General Meeting of the American Society for Microbiology ... show that transcutaneous immunization is an effective way to ...
Cached Biology News:Why the thumb of the right hand is on the left hand side 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 3Preventing ear infections in the future: Delivering vaccine through the skin 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: